This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loganzo, F. Articles by Greenberger, L. M. Search for Related Content PubMed PubMed Citation Articles by Loganzo, F. Articles by Greenberger, L. M.

HTI-286, a Synthetic Analogue of the Tripeptide Hemiasterlin, Is a Potent Antimicrotubule Agent that Circumvents P-Glycoprotein-mediated Resistance in Vitro and in Vivo¹

Oncology Research [F. L., C. M. D., T. A., C. B., S. M., M. H., X. T., C. H., R. H., M. B., L. M. G.] and Chemical Sciences [T. S., G. K., S. A-K., A. Z.], Wyeth Research, Pearl River, New York 10965; The National Cancer Institute Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 [M. S. P., T. F.]; and Department of Chemistry, University of British Columbia, Vancouver, Canada V6T 1Z1 [J. A. N., R. J. A.]

Hemiasterlin is a natural product derived from marine sponges that, like other structurally diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules. Total synthesis of hemiasterlin and its analogues has been accomplished, and optimal pharmacological features of the series have been explored. The biological profile of one analogue, HTI-286, was studied here. HTI-286 inhibited the polymerization of purified tubulin, disrupted microtubule organization in cells, and induced mitotic arrest, as well as apoptosis. HTI-286 was a potent inhibitor of proliferation (mean IC₅₀ = 2.5 ± 2.1 nM in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Resistance to HTI-286 was not detected in cells overexpressing the drug transporters MRP1 or MXR. In athymic mice implanted with human tumor xenografts, HTI-286 administered i.v. in saline inhibited the growth of numerous human tumors derived from carcinoma of the skin, breast, prostate, brain, and colon. Marked tumor regression was observed when used on established tumors that were >1 gram in size. Moreover, HTI-286 inhibited the growth of human tumor xenografts (e.g., HCT-15, DLD-1, MX-1W, and KB-8-5) where paclitaxel and vincristine were ineffective because of inherent or acquired resistance associated with P-glycoprotein. Efficacy was also achieved with p.o. administration of HTI-286. These data suggest that HTI-286 has excellent preclinical properties that may translate into superior clinical activity, as well as provide a useful synthetic reagent to probe the drug contact sites of peptide-like molecules that interact with tubulin.

This article has been cited by other articles:

				A.-M. Liberatore, H. Coulomb, D. Pons, O. Dutruel, P. G. Kasprzyk, M. Carlson, A. S. Nelson, S. P. Newman, C. Stengel, P. Auvray, et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther., August 1, 2008; 7(8): 2426 - 2434. [Abstract] [Full Text] [PDF]

				B. A. Hadaschik, H. Adomat, L. Fazli, Y. Fradet, R. J. Andersen, M. E. Gleave, and A. I. So Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin Clin. Cancer Res., March 1, 2008; 14(5): 1510 - 1518. [Abstract] [Full Text] [PDF]

				I. Zubovych, T. Doundoulakis, P. G. Harran, and M. G. Roth A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance PNAS, October 17, 2006; 103(42): 15523 - 15528. [Abstract] [Full Text] [PDF]

				D. Sampath, L. M. Greenberger, C. Beyer, M. Hari, H. Liu, M. Baxter, S. Yang, C. Rios, and C. Discafani Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models. Clin. Cancer Res., June 1, 2006; 12(11): 3459 - 3469. [Abstract] [Full Text] [PDF]

				M. Hari, F. Loganzo, T. Annable, X. Tan, S. Musto, D. B. Morilla, J. H. Nettles, J. P. Snyder, and L. M. Greenberger Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of {beta}-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther., February 1, 2006; 5(2): 270 - 278. [Abstract] [Full Text] [PDF]

				F. Teraishi, S. Wu, L. Zhang, W. Guo, J. J. Davis, F. Dong, and B. Fang Identification of a Novel Synthetic Thiazolidin Compound Capable of Inducing c-Jun NH2-Terminal Kinase-Dependent Apoptosis in Human Colon Cancer Cells Cancer Res., July 15, 2005; 65(14): 6380 - 6387. [Abstract] [Full Text] [PDF]

				R. Park, C.-C. Chang, Y.-C. Liang, Y. Chung, R. A. Henry, E. Lin, D. E. Mold, and R. C. C. Huang Systemic Treatment with Tetra-O-Methyl Nordihydroguaiaretic Acid Suppresses the Growth of Human Xenograft Tumors Clin. Cancer Res., June 15, 2005; 11(12): 4601 - 4609. [Abstract] [Full Text] [PDF]

				F. Loganzo, M. Hari, T. Annable, X. Tan, D. B. Morilla, S. Musto, A. Zask, J. Kaplan, A. A. Minnick Jr., M. K. May, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in {alpha}-tubulin Mol. Cancer Ther., October 1, 2004; 3(10): 1319 - 1327. [Abstract] [Full Text] [PDF]

				D. Sampath, C. M. Discafani, F. Loganzo, C. Beyer, H. Liu, X. Tan, S. Musto, T. Annable, P. Gallagher, C. Rios, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo Mol. Cancer Ther., September 1, 2003; 2(9): 873 - 884. [Abstract] [Full Text] [PDF]